Neurocognitive Function, Psychosocial Outcome, and Health‐Related Quality of Life of the First‐Generation Metastatic Melanoma Survivors Treated with Ipilimumab

Abstract

A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered with B.U.N. 143201421920.